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Background. The incidence of ductal carcinoma in situ (DCIS) has increased at a fast rate.The aim of this study was to assess the
incidence and treatment in the Netherlands and estimate the excess mortality risk of DCIS. Methods. From the Netherlands Cancer
Registry,adultfemalepatients(diagnosed1997–2005)withDCISwereselected.Treatmentwasdescribedaccordingtoage.Relative
mortality at 10 years of follow-up was calculated by dividing observed mortality over expected mortality. Expected mortality was
calculated using the matched Dutch general population. Results. Overall, 8421 patients were included in this study. For patients
aged 50–64, and 65–74 an increase in breast-conserving surgery was observed over time (P<0.001). For patients over 75 years of
age, 8.0% did not undergo surgery; this percentage remained stable over time (P = 0.07). Overall, treated patients aged >50 years
experienced no excess mortality regardless of treatment (relative mortality 1.0). Conclusion. The present population-based study
of almost 8500 patients showed no excess mortality in surgically treated women over 50 years with DCIS.
1.Introduction
Carcinoma in situ of the breast is deﬁned as abnormal pro-
liferation of epithelial cells that do not trespass the basal
membrane of the breast ductal or lobular system and consist
of a heterogeneous group with diﬀerent types of histology
and also diﬀerent prognosis [1]. The incidence of ductal
carcinoma in situ (DCIS) has increased signiﬁcantly in all
parts of the world including the Netherlands, mainly due
to the introduction of breast cancer screening. The biologic
behavior of DCIS detected by mammography is unclear [2].
Few treated patients will ultimately die of breast cancer;
however, despite the relatively benign nature of DCIS, pa-
tients commonly undergo mastectomy [2–4]. The risks of
overdiagnosis and overtreatment have been discussed in
several studies [2, 3, 5]. Nonetheless, some patients with
DCIS have a less benign course than other patients, and it is
still not possible to identify which DCIS lesions will progress
to invasive carcinoma and in what time interval [6]. Besides,
although DCIS is thought of as an early-stage cancer, lesions
can be quite large [6].
Mostclinicalserieshavefocusedontheriskofbreastcan-
cer recurrence, rather than risk of death per se [3]. Popu-
lation-based reports of actual deaths from breast cancer in
women with DCIS are scarce, but show little excess mortality
[7, 8]. The mass mammographic screening program in the
Netherlands started in 1990/1991 for females aged 50–70
years; in 1997 the upper age limit of the screening program
was increased to 75 years. The aim of this study was to
assess the incidence and treatment of patients with DCIS
in the Netherlands from 1997 to 2005 and to calculate the
number of observed deaths versus the number of expected
deaths based on the general population to estimate the excess
mortality risk of patients diagnosed with DCIS.2 International Journal of Surgical Oncology
Table 1: Characteristics of the population with ductal carcinoma in situ (DCIS) 1997–2005.
Variable Age (years)
<50 50–64∗ 65–75∗ >75 Total
N (%) N (%) N (%) N (%) N (%)
Period
1997–1999 546 (33.2) 1196 (29.1) 529 (27.0) 232 (32.3) 2503 (29.7)
2000–2002 511 (31.1) 1327 (32.5) 723 (36.9) 245 (34.1) 2806 (33.3)
2003–2005 587 (35.7) 1574 (38.4) 709 (36.1) 242 (33.6) 3112 (37.0)
Grade
I 220 (13.4) 482 (11.8) 278 (14.2) 120 (16.7) 1100 (13.1)
II 391 (23.8) 987 (24.1) 507 (25.8) 146 (20.3) 2031 (24.1)
III 644 (39.2) 1726 (42.1) 712 (36.3) 177 (24.6) 3259 (38.7)
Unknown 389 (23.6) 902 (22.0) 464 (23.7) 276 (38.4) 2031 (24.1)
Total 1644 4097 1961 719 8421
∗Invited for mass screening program in the Netherlands.
2. Methods
2.1. Study Population. PALGA, the nationwide Dutch net-
work and registry of histo- and cytopathology, regularly sub-
mits reports of all diagnosed malignancies to the regional
cancer registries. The national hospital discharge databank,
whichreceivesdischargediagnosesofadmittedpatientsfrom
all Dutch hospitals, completes case ascertainment. Trained
cancer registry personnel collect data on diagnosis, staging,
andtreatmentfromthemedicalrecords,includingpathology
and surgery reports, using the registration and coding ma-
nual of the Dutch Association of Comprehensive Cancer
Centers. All data from the regional cancer registries are mer-
ged into the Netherlands Cancer Registry (NCR). From the
NCR database, adult female patients with DCIS diagnosed
between 1997 and 2005 were selected (n = 8421). Patients
with a history of other malignancies were excluded. Histopa-
thology was according to the national protocols in the Ne-
therlands (http://www.oncoline.nl/); central review of the
histopathology was not performed. DCIS was deﬁned ac-
cording to these protocols, and microinvasion (T1mi) was
not included.
2.2. Statistical Analysis. Age was divided into younger than
50, 50–64, 65–75, and 75 years and older where the ﬁrst and
last groups were not invited for screening in the selected
period. Treatment was assessed and stratiﬁed for age. Cha-
nges over time in treatment were studied using chi-square
tests or linear regression analysis. Vital status was established
directly from the patient’s medical record or, in case of miss-
ing values through linkage of cancer registry data with the
municipalpopulationregistrieswhichrecordinformationon
their inhabitant’s vital status. As cause of death is not known
in these cancer registry data, we used relative mortality.
Relative mortality for 10 years of follow-up in the cohort
was calculated by dividing observed mortality in the cohort
at 10 years and expected mortality. Expected mortality was
estimated based on the corresponding (age, sex, and year)
general population (national life tables). National life tables
were obtained from Statistics Netherlands. Mortality was
stratiﬁed for age (to assess diﬀerences in young and elderly
patients) and treatment. The aim of the stratiﬁcation in
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Figure 1: Incidence per 100000 of DCIS in the Netherlands.
t r e a t m e n t sw a sn o tt oc o m p a r et r e a t m e n t sb e t w e e ns t r a t aa s
this would not be possible due to confounding by indication.
Instead, we aimed to assess excess mortality over strata for
each surgical treatment group.
3. Results
Overall, 8421 patients with DCIS were included in this study.
Table 1 shows the characteristics of the study population.
Overall, almost half of all DCIS was diagnosed in patients
aged 50–64 years. Figure 1 shows the incidence per 100000
intheNetherlandsovertheperiod1997–2005.Theincidence
for patients under 50 years remained stable (range 3.1–4.1
per 100000). Incidence for patients aged 75 years and older
remained stable around 12 per 100000 (range 11.7–13.7 per
100000). The incidence slightly increased for those aged 50–
64 years from 37.8 to 41.0 per 100000 and almost doubled
for the age group 66–74 from 24.4 to 44.6 per 100000.
Table 2 shows the treatment for patients with DCIS in
the Netherlands according to age and period of diagnosis.
Patients younger than 50 years often underwent mastec-
tomy (range 55.7% to 60.5%) or breast-conserving surgery
(range 38.9% to 46.3%). Over all the years, only 0.6% did
not undergo surgery. Patients aged 50–64 and 65–74 moreInternational Journal of Surgical Oncology 3
Table 2
(a) SurgicaltreatmentforDCISovertimeintheNetherlands.(b)Adjuvantradiotherapy,overtime,forpatientswithDCISundergoingbreastconserving
surgery (BCS) or mastectomy
Age 1997–1999 2000–2002 2003–2005 P value (years)
Distribution of type of surgery over time (%)
<50
BCS 38.9 46.3 43.6 0.4
MAST 60.5 53.1 55.7
No surgery 0.6 0.6 0.7
50–64
BCS 50.6 56.4 60.7 <0.001
MAST 48.6 43.4 38.2
No surgery 0.8 0.2 1.1
65–74
BCS 50.3 52.6 62.6 <0.001
MAST 48.8 46.2 36.8
No surgery 0.9 1.2 0.6
≥75
BCS 37.1 43.4 44.8 0.07
MAST 55.6 50.9 45.3
No surgery 7.3 5.7 9.9
(b)
Age 1997–1999 2000–2002 2003–2005 P value (years)
Breast-conserving surgery (radiotherapy %)
<50 52.3 59.0 71.7 <0.001
50–64 46.4 69.3 81.6 <0.001
65–75 41.9 60.0 82.4 <0.001
>75 26.3 36.4 51.9 <0.001
Mastectomy (radiotherapy %)
<50 2.0 2.3 5.6 0.004
50–64 1.8 3.0 1.9 0.8
65–75 1.4 4.1 1.2 0.6
>75 0 1.7 1.9 0.2
often underwent breast-conserving surgery, and this pro-
portion signiﬁcantly increased over time (P<0.001). For
the elderly patients ≥75 of age, 7.6% did not undergo sur-
gery, half (50.4%) underwent mastectomy and 42.0% under-
went breast-conserving surgery. Although there was a trend
towardsmorebreast-conservingsurgeryovertime,thistrend
did not reach statistical signiﬁcantly (P = 0.07). For all ages,
adjuvant radiotherapy after breast-conserving surgery in-
creasedovertheyears(allP values<0.001).Inthelastperiod
(2003–2005) the highest percentage of women receiving ra-
diotherapy was in the age 65–75 (82.4%) and the lowest in
the elderly of 75 years and older (51.9%). Radiotherapy after
mastectomy was performed in 3.4% for the patients younger
than 50 years and increased over time from 2.0% to 5.6%
(P = 0.004). In the other age groups, the proportion of pa-
tients undergoing radiotherapy after mastectomy was lower
(2.2% for 50–64 years, 2.4% for 65–75, and 1.2% for the
patients aged 75 years and older, resp.) and did not change
signiﬁcantly over time.
Table 3 shows the observed mortality, the expected mor-
tality based on the general population, and the excess mor-
tality as the ratio of the observed and expected mortality
according to age and treatment (patients who received no
surgery excluded). As radiotherapy after mastectomy was
rarely given, mastectomy with or without radiotherapy were
merged. In patients who underwent breast-conserving sur-
gery (with or without radiotherapy) observed mortality did
not signiﬁcantly exceed expected mortality resulting in ratios
around1.0.Fortheyoungerpatientswhounderwentmastec-
tomy, a signiﬁcant relative mortality was recorded (2.6; P<
0.001). For all strata of patients over the age of 50 years who
underwent mastectomy, observed and expected mortality
were close resulting in a relative mortality of around 1.0.
Overall, all surgically treated patients aged 50 years and older
experienced no excess mortality due to DCIS (ratio of 1.0).
All ages combined, 704 deaths within 10 years were observed
versus 692.1 expected based on the general population with
a ratio of 1.0 expressing no excess mortality of DCIS in the
Netherlands.
4. Discussion
Duetotheintroductionofbreastcancerscreening,incidence
of DCIS has increased dramatically in the last years. Despite
the increasing incidence not many population-based reports4 International Journal of Surgical Oncology
Table 3: Mortality (10 years) of the surgically treated patients with DCIS as compared to the general population according to age, stratiﬁed
by treatment.
Treatment Mortality <50 years 50–64 years 65–75 years >75 years Overall
BCS+RT
Observed 7 34 52 24 117
Expected 5.2 47.5 67.4 26.9 147
Relative mortality 1.4 0.7 0.8 0.9 0.8∗
BCS-RT
Observed 6 36 57 71 170
Expected 3.8 29.4 49.6 74.5 157.3
Relative mortality 1.6 1.2 1.1 1.0 1.1
MAST
Observed 29 61 100 119 309
Expected 11.1 63.3 102.2 131.0 307.5
Relative mortality 2.6∗∗∗ 1.0 1.0 0.9 1.0
Overall
Observed 44 156 233 271 704
Expected 21.6 154.6 243.7 272.2 692.1
Relative mortality 2.0∗∗∗ 1.0 1.0 1.0 1.0
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. Median follow-up: 5.9 years (range 1.2–10.9).
are available that report mortality in this group of women.
The present population-based study of almost 8500 patients
in the Netherlands diagnosed between 1997–2005 shows that
excess mortality was observed for patients younger than
50 years. However, no excess mortality in surgically treated
women over 50 years with DCIS was observed. This means
that after the diagnosis and treatment of DCIS the women
experienced a similar mortality as age and year matched
women in the general population.
4.1. Treatment. Understanding the care received by women
with DCIS is important since it is highly curable, its in-
cidenceisrising(from4.9(1989)to18.6(2008)per100000),
and it is often detected in otherwise healthy women and
thereisapossibilityofovertreatment[9].Overall,45%ofthe
womenintheNetherlandsunderwentmastectomyforDCIS.
In many such patients, mastectomy may have been medically
appropriate, based on patient preferences or the underlying
practice of individual surgeons or institutions [2].
Elderly 75 years or older did not undergo surgery in
7.6%. The reasons for this are unclear, but the result is
probably explained by patients who are unﬁt for surgery due
to many comorbidities or patient preferences [10]. Although
mastectomy results in a cure rate approaching 100%, this
may be overtreatment for some patients, particularly those
with small, mammographically detected lesions [11]. More-
over, there are no randomized studies demonstrating that
mastectomy is better than conservative surgery followed by
radiotherapy for patients with DCIS [1]. The role of radio-
therapy after breast-conserving surgery is supported by large
randomized studies for improvement of local control; how-
ever, none of these studies showed an improvement in sur-
vival or decrease in the risk of distant metastases [1, 12–14].
A recent overview of the randomized trials of radiotherapy
in DCIS showed that radiotherapy reduced the absolute
10-year risk of ipsilateral recurrent DCIS by 8.4% and of
ipsilateral invasive cancer by 8.5% (both P<0.00001) [15].
However, after 10 years of follow-up there was no signiﬁcant
eﬀect on breast cancer mortality, mortality from causes
other than breast cancer, or overall mortality. In the present
study administration of adjuvant radiotherapy after breast-
conserving surgery increased through the years for all ages,
however, remained lower for the elderly aged 75 years and
older. The identiﬁcation of low risk groups within the elderly
patients in whom radiotherapy can be omitted as well as
the development of newer radiation techniques should be a
priority [1].
4.2. Mortality. In the present study, data concerning the
cause of deaths was not available. However, we were able to
estimate the excess mortality by comparing the mortality in
the cohort to mortality in the general population (matched
for sex, year, and age). The present study showed no excess
mortality as compared to the general population in patients
who underwent surgery. Patients who were not surgically
treated were excluded from this analysis as they are probably
considered to frail and by such are not comparable to the
general population. As far as we know, there is only one
publishedpopulation-basedreportofthelikelihoodofbreast
cancer death among women with DCIS (n = 7072) [3].
Breastcancerdeathswereassessedintwogroupsbasedonthe
introduction of screening mammography (1978–1983 and
1984–1989). Among women diagnosed in the early period,
1.5% died of breast cancer within 5 years and 3.4% in 10
years; among the women diagnosed in the latter period 0.7%
died of breast cancer within 5 years and 1.9% in 10 years.
The study of Ernster et al. reported a 10-year standardized
mortalityratioof1.9(95%CI1.2–2.3).Directcomparisonof
the numbers is however not possible as the study of Ernster
calculated the standardized mortality ratio and the present
study the estimated excess (relative) mortality. The latest
numbers in the study of Ernster et al. were from 1984–1989
while the present study describes 1997–2005. Diagnostic
precision (by introduction of the digital mammography)
has probably improved in that period so that patients are
less likely to have unrecognized microinvasive breast cancer
or the proportion of detected DCIS with low malignant
potential has increased [3]. This could also possibly reduceInternational Journal of Surgical Oncology 5
the excess mortality due to breast cancer in our cohort as
compared to Ernster et al.
As almost all women were treated surgically, it is im-
possible to know from these data the extent to which the low
excess mortality from breast cancer among women with
DCIS results from eﬀective treatment or reﬂects the relative
benign nature of the disease or probably both [3]. Remark-
ably, we did ﬁnd an excess mortality in the younger patients
(<50 years) treated with mastectomy. It could be that a large
proportion of this group are BRCA1/2 carriers; however we
have no information to verify this. Mortality was stratiﬁed
for age (to assess diﬀerences in young and elderly patients)
andtreatment.Theaimofthestratiﬁcationintreatmentswas
not to compare treatments between strata as this would not
be possible due to confounding by indication. Instead, we
aimed to assess excess mortality over strata for each surgical
treatment group. In the present study we had no data con-
cerning recurrences in individual patients. However, despite
the fact that some of these women would have experienced
a recurrence, excess mortality due to that recurrence is pre-
sumably low. Approximately half of the recurrences are not
invasive and can be cured with additional surgery [1]. Fur-
thermore, patients who present with invasive cancer have
also a low risk of distant disease [1].
F o rs o m ea g e se x c e s sm o r t a l i t yw a sb e l o w1 . 0( o b s e r v e d
mortality did not exceed expected mortality) indicating that
women with DCIS represent a generally healthy subgroup
of the population which was also conﬁrmed in the study of
Ernster et al. [3]. Women who present for mammography
may have healthier lifestyles than other women; studies have
shown that women who undergo regular screening are more
socioeconomically advantaged and practice more preventive
health behaviors than women who do not [3, 16, 17]. More-
over, breast cancer is more often diagnosed in women with a
higher socioeconomic background.
In conclusion, the present population-based study of
almost 8500 patients in the Netherlands shows no excess
mortality in surgically treated women over 50 years with
DCIS; observed and expected mortality were almost equal
resulting in a relative mortality due to the DCIS of 1.0.
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